## Podcast Reference List By Alyssa Aco

- 1. Zhu J, Pang J, Ji P, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol 2021;93:35-37.
- 2. Hermine O, Mariette X, Tharaux PL, et al. CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. *JAMA Intern Med*. 2021;181(1):32-40.
- 3. Stone JH, Frigault MJ, Serling-Boyd NJ, et al; BACC Bay Tocilizumab Trial Investigators. Efficacy of tocilizumab in patients hospitalized with Covid-19. *N Engl J Med*. 2020;383(24):2333-2344.
- 4. Kim AY, Gandhi RT et al. Covid19: Management in hospitalized adults. UpToDate. Last updated on 14 Sept 2021. From: <a href="https://www.uptodate.com/contents/covid-19-management-in-hospitalized-adults">https://www.uptodate.com/contents/covid-19-management-in-hospitalized-adults</a>
- 5. Iacovellio V. Management of Covid19. DynaMed. University of Alberta Libraries. 2021. From: https://www.dynamed.com/management/management-of-covid-19#
- 6. The COVID-19 Therapeutics Working Group. Alberta Health Services Treatment Guidance for the Management of Adult Hospitalized Patients with COVID-19. Last Updated 30 Sept 2021. From:

  <a href="https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-recommendations.pdf">https://www.albertahealthservices.ca/assets/info/ppih/if-ppih-covid-19-recommendations.pdf</a>
- 7. Bhimraj A, Morgan R et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Last updated, 1 Oct 2021. From: <a href="https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/">https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/</a>
- 8. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. *N Engl J Med*. 2021;384(16):1503-1516.
- 9. Abani O, Abbas A, Abbas F, et al; RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2021;397(10285):1637-1645.
- 10. Gordon AC, Mouncey PR, Al-Beidh F, et al; REMAP-CAP Investigators. Interleukin-6 receptor antagonists in critically ill patients with Covid-19. *N Engl J Med*. 2021;384(16):1491-1502.
- 11. Shankar-Hari M et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. *JAMA* 2021 Jul 6; [e-pub]. (https://doi.org/10.1001/jama.2021.11330)